Drugs / NNC0519-0130
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07004322 | May 2025 → Jan 2026 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06718998 | Nov 2024 → Jan 2026 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06567041 | Aug 2024 → Dec 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06513104 | Jul 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06370819 | Apr → Nov 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05870670 | May → Oct 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05363774 | Apr 2022 → Apr 2024 | diabetes mellitus, noninsulin-dependent, 2 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06717698 | Dec 2024 → Sep 2026 overdue | chronic kidney disease | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT06326047 | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06326060 | Mar 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0519-0130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06513104 ↗ |
| Route | Subcutaneous | “subcutaneous NNC0519-0130” NCT05363774 ↗ |